July 31, 2025 · Form 4 insider transaction
Frankenius Equity AB sold 230,000 shares of TriSalus Life Sciences, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 263 days after the transaction.
Represents conversion price pursuant to an offer (the "Offer") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share.; On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer.